ABLYNX TO PRESENT AT THE JEFFERIES LONDON HEALTHCARE CONFERENCE 2016

GHENT, Belgium, Nov. 09, 2016 -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that its CEO, Dr Edwin Moses, will present a company update at the Annual Jefferies Healthcare Conference in London on Wednesday, 16 November 2016 at 12:40 p.m. GMT (01:40 p.m. CET).

The presentation will be webcast live and can be accessed on the day via this link. A replay of the webcast will be available on the Company's website, under the news & events section, for 90 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  [email protected]

Marieke Vermeersch
Director IR & Corporate Communications
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  [email protected]
Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: [email protected]

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/f1be51d2-b527-4a6f-8c55-157a55b6b7bd